Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14081843 | 0.89 | HCRTR1 (0.39) | ROCK2HCRTR1HCRTR2TRPV1TLR8 | |
| SCHEMBL13594853 | 0.87 | HCRTR1 (0.42) | ROCK2HCRTR1HCRTR2TLR8TLR7 | |
| SCHEMBL14071788 | 0.84 | HCRTR1 (0.41) | ROCK2HCRTR1HCRTR2TLR8TLR7 | |
| SCHEMBL4411420 | 0.84 | HCRTR1 (0.41) | ROCK2HCRTR1HCRTR2TLR8TLR7 | |
| SCHEMBL4411423 | 0.79 | MEN1 (0.34) | ROCK2HCRTR1HCRTR2LMNAMEN1 | |
| SCHEMBL14071842 | 0.79 | HCRTR1 (0.40) | ROCK2HCRTR1HCRTR2TLR8TLR7 | |
| SCHEMBL14071838 | 0.79 | HCRTR1 (0.40) | ROCK2HCRTR1HCRTR2TLR8TLR7 | |
| SCHEMBL4406340 | 0.79 | HCRTR1 (0.40) | ROCK2HCRTR1HCRTR2TLR8TLR7 | |
| SCHEMBL14477477 | 0.78 | HCRTR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL5962927 | 0.77 | POLB (0.48) | ROCK2HCRTR1HCRTR2TRPV1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664049-B1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2009-12-23 | — | — | EP | disclosed |
| US-7429658-B2 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1664049-A1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023814-A1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SBDS, DRD2, GRIN2D | ROCK2 3724/4885HCRTR1 1486/4885HCRTR2 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.